Quarterly ResultAug 10, 2026, 04:40 PM
BridgeBio Q2 Net Product Revenue +272%; Multiple NDAs Accepted by FDA
AI Summary
BridgeBio Pharma reported a substantial increase in net product revenue for the six months ended June 30, 2026, reaching $403.0 million, a 272% rise year-over-year. The company also saw its net loss decrease to $322.4 million from $353.4 million in the prior year. This period was marked by significant regulatory progress, including the FDA's acceptance of New Drug Applications for BBP-418 with Priority Review and encaleret, alongside a recent NDA submission for low-dose infigratinib.
Key Highlights
- Net product revenue for six months ended June 30, 2026, increased 272% to $403.0 million.
- Total revenues for six months ended June 30, 2026, rose 93% to $438.2 million.
- Net loss for six months ended June 30, 2026, improved to $(322.4) million from $(353.4) million.
- Net loss per share was $(1.62) for the six months ended June 30, 2026.
- FDA accepted NDA for BBP-418 with Priority Review, PDUFA date November 27, 2026.
- FDA accepted NDA for encaleret, PDUFA target action date May 8, 2027.
- Cash and cash equivalents stood at $677.9 million as of June 30, 2026.
- Research and development expenses increased to $276.1 million for the six-month period.
Price Impact
More from BBIO